Want to see HK:6660 full AI Analyst Report?
Top Page
AIM Vaccine Co., Ltd. Class H
(6660)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$1.50
▼(-57.02% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial performance (revenue decline, large losses, negative ROE, and ongoing free-cash-flow burn despite positive operating cash flow). Technicals are mixed with only a modest short-term bounce and still-weak longer-term trend signals, while valuation offers limited support because profitability is negative and no dividend yield is available.
Positive Factors
Strong Gross Margins
Strong gross margins indicate that the company’s vaccine products retain meaningful economics before operating expenses. If maintained, this provides a foundation for eventual earnings recovery, supports reinvestment in research and commercialization, and offers some resilience as revenue conditions fluctuate over the coming quarters.
Negative Factors
Revenue Decline
The return to revenue contraction indicates that commercial growth has not yet become consistent. Continued top-line weakness could reduce operating leverage, limit the resources available for vaccine development, and make it harder for the company to absorb fixed costs while rebuilding its product performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Strong gross margins indicate that the company’s vaccine products retain meaningful economics before operating expenses. If maintained, this provides a foundation for eventual earnings recovery, supports reinvestment in research and commercialization, and offers some resilience as revenue conditions fluctuate over the coming quarters.
Read all positive factors
AIM Vaccine Co., Ltd. Class H (6660) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.88B
Dividend YieldN/A
Average Volume (3M)118.69K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-18.45%
EPS Growth-151.15%
CountryHK
Employees1,466
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding507,673,700
10 Day Avg. Volume111,040
30 Day Avg. Volume118,693
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.28
Price to Sales (P/S)3.06
P/FCF Ratio-20.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$3.68B
AIM Vaccine Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is...
AIM Vaccine Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 996.81M | 1.15B | 1.29B | 1.19B | 1.26B | 1.57B |
| Gross Profit | 648.28M | 760.20M | 953.51M | -611.21M | 1.03B | 1.29B |
| EBITDA | -32.42M | -49.54M | -57.89M | -2.05B | -242.03M | -451.71M |
| Net Income | -665.47M | -675.46M | -277.23M | -1.30B | -319.60M | -692.77M |
Balance Sheet | ||||||
| Total Assets | 6.33B | 6.55B | 7.31B | 7.26B | 8.88B | 8.07B |
| Cash, Cash Equivalents and Short-Term Investments | 193.15M | 384.72M | 594.87M | 736.41M | 818.91M | 746.74M |
| Total Debt | 1.77B | 1.76B | 1.84B | 1.80B | 1.40B | 650.43M |
| Total Liabilities | 3.53B | 3.61B | 3.70B | 3.37B | 3.01B | 2.37B |
| Stockholders Equity | 2.64B | 2.76B | 3.37B | 3.64B | 4.96B | 4.89B |
Cash Flow | ||||||
| Free Cash Flow | -95.56M | -171.39M | -139.09M | -467.14M | -966.96M | -1.05B |
| Operating Cash Flow | 116.22M | 67.47M | 99.19M | -165.50M | -110.32M | 93.40M |
| Investing Cash Flow | -66.37M | -107.73M | -162.34M | -271.96M | -858.15M | -1.34B |
| Financing Cash Flow | -185.62M | -111.65M | -26.22M | 362.07M | 980.37M | 788.02M |
AIM Vaccine Co., Ltd. Class H Technical Analysis
Negative
3.49
Price Trends
1.67
Negative
1.66
Negative
2.28
Negative
Market Momentum
-0.05
Positive
43.23
Neutral
34.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6660, the sentiment is Negative. The current price of 3.49 is above the 20-day moving average (MA) of 1.63, above the 50-day MA of 1.67, and above the 200-day MA of 2.28, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 34.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6660.
AIM Vaccine Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% | |
64 Neutral | HK$79.58B | -14.95 | -16.23% | 0.35% | 53.48% | -120.02% | |
53 Neutral | HK$80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$1.88B | -2.43 | -24.66% | ― | -18.45% | -151.15% | |
44 Neutral | HK$708.65M | -3.48 | -7.32% | ― | ― | 51.71% | |
43 Neutral | HK$1.62B | 1.61 | -64.89% | ― | -99.15% | ― |
* Healthcare Sector Average
HK:6660
AIM Vaccine Co., Ltd. Class H
1.54
-2.38
-60.74%
HK:1548
Genscript Biotech
35.02
18.92
117.52%
HK:2269
Wuxi Biologics (Cayman)
44.48
8.28
22.87%
HK:2137
Brii Biosciences Limited
0.98
-0.84
-46.12%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
26.98
1.25
4.86%
HK:2197
Clover Biopharmaceuticals Ltd.
1.25
-0.95
-43.18%
AIM Vaccine Co., Ltd. Class H Corporate Events
AIM Vaccine Delays EGM to Revise Domestic Unlisted Share Issuance Plan
Sep 1, 2026
AIM Vaccine Co., Ltd. has adjourned its second extraordinary general meeting originally scheduled for September 7, 2026, as the board is considering amendments to its issuance plan for domestic unlisted shares under a specific mandate. The company...
AIM Vaccine Seeks Approval for High-Potency Human Diploid Cell Rabies Shot
Aug 24, 2026
AIM Vaccine Co., Ltd. has submitted an application to China’s National Medical Products Administration for marketing registration of its independently developed iterative high-potency human diploid cell rabies vaccine. Phase III trial result...
AIM Vaccine Interim Revenue Slides as Losses Narrow Slightly
Aug 23, 2026
AIM Vaccine Co., Ltd., a mainland Chinese biopharmaceutical group listed in Hong Kong, specializes in developing, manufacturing and selling human vaccines. It targets healthcare providers and public health markets, competing on product portfolio a...
AIM Vaccine Revises Domestic Share Issuance and Secures Key Subscriptions
Aug 18, 2026
AIM Vaccine has approved amendments to its previously authorized issuance of domestic unlisted shares, expanding the range from not less than 40 million to not more than 80 million shares and fixing the issue price at RMB1.07 per share. The revise...
AIM Vaccine Seeks Shareholder Nod for Private Domestic Share Issue and Dual Mainland Listings
Aug 18, 2026
AIM Vaccine Co., Ltd., a Hong Kong-listed biopharmaceutical company focused on vaccine development and commercialization, plans to broaden its capital market presence by listing its domestic unlisted shares on the National Equities Exchange and Qu...
AIM Vaccine Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 12, 2026
AIM Vaccine Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, specializes in vaccine development and manufacturing for public health needs and is governed by a board comprising executive, non-executive and independent non-execu...
AIM Vaccine Advances Serum-Free Rabies Shot Toward China Market Approval
Aug 3, 2026
AIM Vaccine’s wholly owned subsidiary AIM Rongyu has completed submission of supplementary data to China’s National Medical Products Administration for market registration of its self-developed serum-free iterative rabies vaccine, foll...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.